New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer

medicalxpress - Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to an international phase 3 cli…

AI Summary: Practice‑changing data and a network meta‑analysis have clarified perioperative strategies for muscle‑invasive bladder cancer, showing that certain neoadjuvant and adjuvant approaches improve survival and reduce recurrence. Recent trial results and comparative evidence are prompting shifts in treatment sequencing for cisplatin‑eligible patients, moving the needle on standards of care.